The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)
نویسندگان
چکیده
منابع مشابه
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene
Gastrointestinal stromal tumors (GIST) carrying the D842V activating mutation in the platelet-derived growth factor receptor alpha (PDGFRA) gene are a very rare subgroup of GIST (about 10%) known to be resistant to conventional tyrosine kinase inhibitors (TKIs) and to show an indolent behavior. In this study, we performed an integrated molecular characterization of D842V mutant GIST by whole-tr...
متن کاملCrenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
PURPOSE To determine the potential of crenolanib, a potent inhibitor of PDGFRA, to treat malignancies driven by mutant PDGFRA. EXPERIMENTAL DESIGN The biochemical activity of crenolanib was compared with imatinib using a panel of PDGFRA-mutant kinases expressed in several different cell line models, including primary gastrointestinal stromal tumors (GIST) cells. The antiproliferative activity...
متن کاملLaparoscopic Resection of Gastrointestinal Stromal Tumors (gist)
BACKGROUND Gastrointestinal mesenchymal or stromal tumors (GIST) are lesions originated on digestive tract walls, which are treated by surgical resection. Several laparoscopic techniques, from gastrectomies to segmental resections, have been used successfully. AIM Describe a single center experience on laparoscopic GIST resection. METHOD Charts of 15 operated patients were retrospectively r...
متن کاملGastrointestinal Stromal Tumors (GIST) and Their Management.
Gastrointestinal stromal tumor (GIST) is the most common form of sarcoma and can vary in size and clinical outcome from an incidental finding at the time of surgery to life-threatening metastatic disease. Surgery is the standard of care for primary disease, and the oral drug imatinib is the standard of care for metastatic disease. Sunitinib was approved in the United States in early 2006 for GI...
متن کاملGastrointestinal stromal tumors (GIST): new treatment expectations.
Gastrointestinal stromal tumors (GIST) have been known for over twenty years, but until ten years ago they were a heterogeneous group of neoplasms which included leiomyomas, leiomyosarcomas, leiomyoblastomas and schwannomas. They represent approximately 0.5-3 % of all primary tumors of the gastrointestinal tract, only 5 % of visceral sarcomas, but 80 % of malignant tumors originated in the mese...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancers
سال: 2021
ISSN: 2072-6694
DOI: 10.3390/cancers13040705